

December 13, 2013



AxoGen CEO Karen Zaderej Interview on Clear Channel Business Talk Radio DFW1190AM by Michael Yorba

Interview Today at 3:45PM EST -- Streamed via iHeart Radio

ALACHUA, FL -- (Marketwired) -- 12/13/13 -- AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced CEO Karen Zaderej will be interviewed live today at 3:45pm EST on Clear Channel's business talk radio show "The Trader Network" by host Michael Yorba.

Tune in today to listen to live on-air interview:

Live Link: <http://www.iheart.com/live/4276/?autoplay=true>

Date: Dec 13th, 2013

Time: 2:45pm CST | 3:45pm EST | 12:45pm PST

Network: Clear Channel

Show: The Trader Network

Station: [DFW 1190AM](#)

Host: Michael Yorba

The interview will cover:

- How AxoGen is changing the way the world thinks about nerve repair.
- The over \$1.6 billion market for peripheral nerve repair in the United States and the nearly 1 million nerve surgeries performed annually.
- AxoGen's full suite of nerve repair products including Avance® Nerve Graft, the only commercially available processed nerve allograft; AxoGuard® Nerve Protector; and AxoGuard® Nerve Connector.
- AxoGen's mission to create a world where all patients are offered choices for surgical repair of peripheral nerve.
- AxoGen's recent up listing to NASDAQ (AXGN) and its 49% revenue growth reported for the Third Quarter of 2013

About Clear Channel

Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. [DFW1190AM.com](#) Dallas-Ft. Worth, TX www.clearchannel.com

About Michael Yorba

Michael Yorba -- featured host of Clear Channels DFW 1190AM in Dallas-Ft. Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company's innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen's products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. www.AxoGenInc.com or follow us on twitter @AxoGen.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2479892

Company Contact:

AxoGen, Inc.
Greg Freitag
CFO & General Counsel
Tel: +1 (612) 619-6324
InvestorRelations@AxoGenInc.com

Press | Media Contact

Matthew BIRD
President
MUNCmedia Public Relations
Tel: (917) 409-8211
Email: matt.bird@muncmedia.com

A www.1800PublicRelations.com PR Event

Source: AxoGen, Inc.